[1]王小燕.UHRF1检测在良恶性胸腔积液鉴别诊断中的研究[J].现代检验医学杂志,2017,32(04):91-92,96.[doi:10.3969/j.issn.1671-7414.2017.04.025]
　WANG Xiao-yan.Study on the Detection of UHRF1 in the Differential Diagnosis of Benign and Malignant Pleural Effusion[J].Journal of Modern Laboratory Medicine,2017,32(04):91-92,96.[doi:10.3969/j.issn.1671-7414.2017.04.025]
点击复制

UHRF1检测在良恶性胸腔积液鉴别诊断中的研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年04期
页码:
91-92,96
栏目:
论著
出版日期:
2017-07-25

文章信息/Info

Title:
Study on the Detection of UHRF1 in the Differential Diagnosis of Benign and Malignant Pleural Effusion
文章编号:
1671-7414(2017)04-091-03
作者:
王小燕
南京医科大学附属江宁医院检验科,南京 211100
Author(s):
WANG Xiao-yan
Department of Clinical Laboratory, Jiangning Hospital Affiliated to Nanjing Medical University,Nanjing 211100,China
关键词:
UHRF1;  胸腔积液;  ELISA法
分类号:
R446.19
DOI:
10.3969/j.issn.1671-7414.2017.04.025
文献标志码:
A
摘要:
目的 探讨泛素样含PHD和环指域1(ubiquitin-like withPHD and ringfinger domains 1,UHRF1)在良恶性胸腔积液中的表达及临床意义。方法 收集南京市江宁医院2015年11月～2017年2月入院的130例胸腔积液患者,其中肺癌引起的恶性胸腔积液54例,肺部良性病变胸腔积液76例。肺部良性病变胸腔积液中,结核性胸腔积液36例,炎症性胸腔积液40例。采用酶联免疫吸附试验(enzyme-linkedimmunosorbent assay,ELISA)分别检测各组UHRF1水平,并分析其与临床病理的关系。结果 肺癌患者胸腔积液UHRF1水平(437.28±140.05 ng/L)高于肺部良性病变者(338.47±163.72 ng/L),两组比较差异有统计学意义(t=3.596,P=0.0005)。非腺癌患者UHRF1水平(470.59±127.74 ng/L)高于腺癌患者(377.78±145.81 ng/L),差异有统计学意义(t=2.329,P=0.023)。良性病变组中结核性胸腔积液UHRF1水平为365.51±167.54 ng/L,与炎性胸腔积液(314.13±158.34 ng/L)相比较,差异无统计学差异(t=1.374,P=0.174)。良恶性胸腔积液UHRF1水平均与年龄、性别及吸烟史无关。结论 UHRF1是诊断良恶性胸腔积液一个潜在指标。
Abstract:
Objective To investigate the expression and clinical significance of ubiquitin-like with PHD and ringfinger domains 1(UHRF1)in benign and malignant pleural effusion.Methods From November,2015 to February,2017,130 cases of pleural effusion were collected inJiangning hospital of Nanjing,including 54 cases of malignant pleural effusioncaused by lung cancer and 76 cases of lung benign pleural effusion.And the latter contained 36 cases of tuberculous pleural effusion and 40 cases of inflammatory pleural effusion.Enzyme-linked immunosorbent assay(ELISA)were used to detect the level of UHRF1 in each group,and the relationship between UHRF1 and clinical pathology was analyzed.Results The level of UHRF1 437.28±140.05 ng/L in patients with lung cancer was higher than that 338.47±163.72 ng/L in patients with benign lung diseases,and the differences were statistically significant(t=3.596,P=0.0005).The level of UHRF1 470.59±127.74 ng/L in patients with non- adenocarcinoma was higher than that 377.78±145.81 ng/L in patients with adenocarcinoma,and the differences were statistically significant(t=2.329,P=0.023).In group with benign lesion,there were no significant differences(t=1.374,P=0.174)between the level of UHRF1365.51±167.54 ng/L in tuberculous pleural effusion and the level of UHRF1 314.13±158.34 ng/L in inflammatory pleural effusion.And the level of UHRF1 in benign and malignant pleural effusion was not related to age,sexuality and smoking history.Conclusion UHRF1 is a potential marker in thedifferential diagnosis of benign and malignant pleural effusion.

参考文献/References:

[1] 冯纾琪,黄钰君,廖春淼,等.用ROC曲线分析胸腔积液和血清肿瘤标志物联合检测对肺癌的诊断价值[J].现代检验医学杂志,2013,28(1):127-129,132. Feng SQ,Huang YJ,Liao CM,et al.Diagnosis value of the lung cancer through analysis the tumor markers of pleural effusion and serum detection with ROC curve[J].J Mod Lab Med,2013,28(1):127-129,132.
[2] Mousli M,Hopfner R,Abbady AQ,et al.ICBP90 belongs to a new family ofproteins with an expression that is deregulated in cancer cells[J].British Journal of Cancer,2003,89(1):120-127.
[3] Kim KB,Son HJ,Choi S,et al.H3K9 methyltransferase G9a negatively regulates UHRF1 transcription during leukemia cell differentiation[J].Nucleic Acids Res,2015,43(7):3509-3523.
[4] Guan D,Factor D,Liu Y,et al.The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein[J].Oncogene,2013,32(33):3819-3828.
[5] Alhosin M,Sharif T,Mousli M,et al.Down-regulation of UHRF1,associated with re-expression of tumor suppressor genes,is a common feature of naturalcompounds exhibiting anti-cancer properties[J].J Exp Clin Cancer Res,2011,30(1):41.
[6] Zhang Y,Huang Z,Zhu Z,et al.Upregulated UHRF1 promotes bladder cancercell invasion by epigenetic silencing of KiSS1[J].PLoS One,2014,9(10):e104252.
[7] Babacan NA,Egilmez HR,Yücel B,et al.The prognostic value of UHRF-1and p53 in gastric cancer[J].Saudi Journal of Gastroenterology,2016,22(1):25-29.
[8] Abu-Alainin W,Gana T,Liloglou T,et al.UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis[J].J Pathol,2016,238(3):423-433.
[9] Zhu M,Xu Y,Ge M,et al.Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell proliferation and apoptosis[J].Cancer Science,2015,106(7):833-839.
[10] Liang D,Xue H,Yu Y,et al.Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma[J].Int JClin Exp Pathol,2015,8(8):9416-9421.
[11] Geng Y,Gao Y,Ju H,et al.Diagnostic and prognostic value of plasma and tissue ubiquitin-like,containing PHD and RING finger domains 1 in breast cancer patients[J].Cancer Science,2013,104(2):194-199.
[12] Ge M,Gui Z,Wang X,et al.Analysis of the UHRF1 expression in serum and tissue for gastric cancer detection[J].Biomarkers,2015,20(3):183-188.
[13] Sidhu H,Capalash N.UHRF1:the key regulator of epigenetics and molecular target for cancer therapeutics[J].Tumour Biol,2017,39(2):1010428317692205.
[14] Unoki M,Daigo Y,Koinuma J,et al.UHRF1 is a novel diagnostic marker of lung cancer[J].British Journal of Cancer,2010,103(2):217-222.
[15] Daskalos A,Oleksiewicz U,Filia A,et al.UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer[J].Cancer,2011,117(5):1027-1037.

相似文献/References:

[1]张 华a,李小侠a,刘 婧a,等.胸腔积液中CEA,FDP和DD检测对良恶性胸腔积液鉴别的意义[J].现代检验医学杂志,2017,32(06):122.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHANG Huaa,LI Xiao-xiaa,LIU Jinga,et al.Diagnosis Value of CEA,FDP and DD in the Pleural Effusion Specimens for Benign and Malignant Pleural Effusion[J].Journal of Modern Laboratory Medicine,2017,32(04):122.[doi:10.3969/j.issn.1671-7414.2017.06.001]

备注/Memo

备注/Memo:
基金项目:南京市卫生局基金(YKK15202)。 作者简介:王小燕(1976-),女,本科,副主任技师,研究方向:临床免疫学检验,E-mail:jnyydhxfgs@163.com。
更新日期/Last Update: 1900-01-01